Jingtian Signs MOU with Bonokon to Expand China Topical Formulation Market

Jingtian (6917-TW) has signed a Memorandum of Understanding (MOU) with Bonokon (Beijing) to jointly expand the Chinese topical formulation market. Through this collaboration, both parties will work together on clinical validation and drug approval processes for products in China, accelerating their commercialization.

Jingtian stated that this partnership establishes a strategic cooperation framework, integrating Jingtian’s R&D strengths in novel topical formulations with Bonokon’s robust local clinical regulatory capabilities and commercialization resources. Together, they aim to build a comprehensive commercialization platform spanning technology development, clinical validation, and market sales.

Chairman Ai-Chun Wang explained that under this agreement with Bonokon, novel topical formulations will serve as the core development area, continuously expanding niche generic drugs and new formulation product lines while advancing market positioning.

Wang noted that Bonokon specializes in high-end inhaled API development, micronization technology, and CDMO services, possessing strong capabilities in China’s pharmaceutical registration system and distribution channel advantages. The alliance enables both parties to effectively shorten the product development-to-market timeline while reducing regulatory and commercialization risks.

Benefiting from increased royalty income and strong sales performance of its key generic drugs, Jingtian reported August revenue of RMB 1.62 million, representing a 74.22% month-over-month increase and a 34.49% year-over-year rise—the highest monthly revenue in company history. Cumulative revenue for the first eight months reached RMB 8.39 million, up 5.49 times year-over-year, also setting a new historical high.

With key new drugs entering the harvest phase of development, generic drug sales on a growth trajectory, and partnership benefits becoming evident, Jingtian holds a cautiously optimistic outlook for its operations over the next two years.